Table 1.
Overview of the described preclinical and clinical studies using 89Zr-labeled antibodies.
| Target | Type of tumor | Targeting vector |
|---|---|---|
| CD147 | Pancreas | 059-053 |
| CD20* | Non-Hodgkin's lymphoma | ibritumomab tiuxetan |
| CD44v6* | Head and neck squamous cell carcinoma | cmAb U36 |
| EGFR | Multiple | Cetuximab |
| EGP-1 | Prostate | hRS7 |
| GPC3 | Liver | αGPC3 |
| HER1 | Colorectal | Panitumunmab |
| HER2* | Breast and ovarian | Trastuzumab |
| IGF-1R | Triple negative breast cancer | R1507 |
| MET | Head and neck squamous cell carcinoma and gastric | DN30 |
| MN/CA IX | Renal cell carcinoma | cG250 |
| PSMA | Prostate | 7E11 |
| PIGF | Liver | RO5323441 |
| VEGF* | Breast, head, and neck squamous cell carcinoma and ovarian | Bevacizumab |
*Targets evaluated in clinical studies.